Skip to main content
Article
Fibronectin: How Its Aberrant Expression in Tumors May Improve Therapeutic Targeting
Journal of Cancer
  • Jennifer Peyling Wang
  • Abigail Hielscher, Philadelphia College of Osteopathic Medicine
Document Type
Article
Publication Date
2-25-2017
Abstract

Fibronectin is a matrix glycoprotein which has not only been found to be over-expressed in several cancers, but has been shown to participate in several steps of tumorigenesis. The purpose of this review is to illustrate how aberrant fibronectin expression influences tumor growth, invasion, metastasis and therapy resistance. In particular, this review will focus on the interactions between cell receptor ligands and fibronectin and how this interaction influences downstream signaling events that aid tumor progression. This review will further discuss the possible implications of therapeutic drugs directed against fibronectin and/or cellular interactions with fibronectin and will additionally discuss novel approaches by which to limit intra- and extra-tumoral fibronectin expression and the cellular events which lead to aberrant fibronectin expression. It is anticipated that these studies will set a basis for future research that will not only aid understanding of fibronectin and its prognostic significance, but will further elucidate novel targets for therapeutics.

PubMed ID
28367247
Comments

This article was published in Journal of Cancer, Volume 8, Issue 4, Pages 674-682.

The published version is available at http://dx.doi.org/10.7150/jca.16901.

Copyright © 2017. CC BY-NC.

Citation Information
Jennifer Peyling Wang and Abigail Hielscher. "Fibronectin: How Its Aberrant Expression in Tumors May Improve Therapeutic Targeting" Journal of Cancer Vol. 8 Iss. 4 (2017) p. 674 - 682
Available at: http://works.bepress.com/abigail_hielscher/14/